Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

被引：0
|
作者：
Schonhoft, Joseph [1 ]
Jendrisak, Adam [1 ]
Lee, Jerry [1 ]
Rodriguez, Angel [1 ]
Sutton, Ramsay [1 ]
Wang, Yipeng [1 ]
Dittamore, Ryan [1 ]
Landers, Mark [1 ]
机构：
[1] Epic Sci, San Diego, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2228
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Wise, David
    Louw, Jessica
    Krupa, Rachel
    Schreiber, Nicole A.
    Sawyers, Charles L.
    Dittamore, Ryan Vance
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Zukotynski, Katherine A.
    Jadvar, Hossein
    Cho, Steve Y.
    Kim, Chun Ki
    Cline, Kathryn
    Emmenegger, Urban
    Hotte, Sebastien J.
    Pond, Gregory Russell
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Karunaratna, Nathasha
    Jensen, Andrew
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Spain, Lavinia
    Azad, Arun
    Kwan, Edmond M.
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Gibbs, Peter
    Tran, Ben
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 58 - 58
  • [35] Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Henriquez, Ivan
    Roach, Mack I. I. I. I. I. I.
    Morgan, Todd M.
    Bossi, Alberto
    Gomez, Junior A.
    Abuchaibe, Oscar
    Counago, Felipe
    BIOMEDICINES, 2021, 9 (09)
  • [36] Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations.
    Yip, Steven
    Angeles, Arkhjamil
    Beigi, Arshia
    Warner, Evan W.
    Khalaf, Daniel
    Sunderland, Katherine
    Vandekerkhove, Gillian Rae
    Annala, Matti
    Schrader, Kasmintan A.
    Wyatt, Alexander William
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] A Circulating Tumor Cell RNA Assay for Prognostication of Patients with Metastatic Castration-resistant Prostate Cancer
    Wang, Jasmine
    Kim, Minhyung
    Teng, Pai-Chi
    Jan, Yu Jen
    Chen, Jie-Fu
    Shi, Lucy Ruoxi
    You, Sungyong
    Tseng, Hsian-Rong
    Posadas, Edwin
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1568 - S1569
  • [38] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D)
    Peer, Avivit
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Boursi, Ben
    Leibowitz-Amit, Raya
    Berger, Raanan
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Pili, Roberto
    Hammers, Hans J.
    Sinibaldi, Victoria J.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [39] The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Chowdhury, S.
    Abida, W.
    Arranz Arija, J.
    Daugaard, G.
    Fizazi, K.
    Gez, E.
    Heidenreich, A.
    Joly Lobbedez, F.
    McDermott, R.
    Merseburger, A. S.
    Piulats Rodriguez, J. M.
    Sautois, B.
    Sridhar, S.
    Sternberg, C. N.
    Watkins, S.
    Simmons, A.
    Shetty, S.
    Golsorkhi, A.
    Ryan, C. J.
    Scher, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
    Stewart, T. F.
    Gedrich, R.
    Saha, J.
    Chirnomas, D.
    Edwards, M.
    Lang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1188 - S1188
12345